The FDA-centric Australian CRO championing innovative US and global biotech firms.
Delivering high quality clinical research at a fraction of the cost.
Recently featured in
Why do so many US and global biotech firms bring their early-stage clinical trials to Australia?
Government Grant Access
43.5% Government R&D tax incentive (even for foreign companies)
Fast, High-Quality Research
Fast start-up time without sacrificing quality – 8-12 weeks on average (no IND required)
FDA Regulatory Expertise
iNGENū's in-house regulatory team specializes in US FDA Pre-INDs and IND submissions
Diverse Therapeutic Specialty Leaders
Our team comprises physician and scientific specialists in a wide variety of areas
Our trusted partners
Our Mission
Our core mission is to create access to high quality clinical research globally by removing financial and other unnecessary barriers.
![Giles-Moss](https://www.ingenucro.com/hs-fs/hubfs/Giles-Moss-1.png?width=182&height=180&name=Giles-Moss-1.png)
"We have been using iNGENū for a Phase 1, first-in-human trial of our investigational drug. We have used iNGENū for: Medical writing, project management, clinical data management and full end-to-end, clinical trial execution and monitoring.
We have been very happy with all aspects of the management of the clinical trial and have been particularly impressed by the out-of-the-box creative solutions to speed up and reduce overheads for our company during this clinical trial."
Giles Moss
Chief Executive Officer